Filing summary
Entity and period discrepancy: The request identifies Lite Strategy, Inc. and 2014 Q1, but the supplied filing is MEI Pharma, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2015 (fiscal 2016 Q1). This summary reflects the supplied filing, not the requested entity or period.
Business context and reporting period
MEI Pharma is a clinical-stage oncology company with no revenue. Its development portfolio includes Pracinostat, ME-344, and PWT143. The statements compare the three months ended September 30, 2015 with the three months ended September 30, 2014; balance sheet figures compare September 30, 2015 with June 30, 2015.
Key financial metrics
| Metric | Three months ended September 30, 2015 | Prior comparable period |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $2.816 million | $6.566 million |
| General and administrative expense | $1.830 million | $2.439 million |
| Total operating expenses / operating loss | $4.646 million | $9.005 million |
| Net loss | $4.620 million | $8.993 million |
| Basic and diluted net loss per share | $0.13 | $0.42 |
| Net cash used in operating activities | $5.761 million | $6.731 million |
At September 30, 2015, cash, cash equivalents, and short-term investments totaled $58.018 million, comprising $17.876 million cash and equivalents and $40.142 million in short-term U.S. government securities. Total assets were $59.068 million; current liabilities were $3.127 million; and stockholders’ equity was $55.941 million. No debt is reported. With no revenue, profit and operating margin are not meaningful.
Cash and equivalents declined by $0.846 million during the quarter. Investing activities provided $4.915 million, primarily as investment maturities exceeded purchases; there were no financing cash flows. The company reported accumulated deficit of $160.759 million.
Changes versus prior comparable period
- Net loss narrowed by $4.373 million, while operating expenses fell by $4.359 million.
- R&D expense decreased by $3.750 million, primarily reflecting lower drug manufacturing and Pracinostat Phase II trial costs. G&A expense decreased by $0.609 million, primarily due to lower share-based compensation.
- Operating cash use decreased by $0.970 million.
- Weighted-average shares increased to 34.334 million from 21.652 million; per-share loss declined from $0.42 to $0.13.
Outlook, commentary, risks, and unusual items
- Management expected existing cash, cash equivalents, and short-term investments to fund operations through at least calendar year 2016. It anticipated seeking future equity financing or strategic partnerships. The company expected operating losses and negative operating cash flows to continue.
- Pracinostat’s Phase II combination study in higher-risk MDS did not improve the primary endpoint, overall complete-remission rate, versus azacitidine alone; survival endpoints remained immature. In a separate elderly AML study, 27 of 50 patients achieved CR, CRi, or morphologic leukemia-free state; median overall survival had not been reached.
- The company expected to initiate a PWT143 study in patients with hematologic cancers in the first half of calendar 2016. ME-344 combination-trial patients remained under follow-up.
- Risks include clinical-trial failure or delay, regulatory uncertainty, dependence on additional financing and third-party arrangements, commercialization and market-acceptance challenges, manufacturing costs, and intellectual-property risks. Management reported no material changes to the risk factors in its latest annual report.
- Potential S*Bio milestone payments could total up to $75.2 million if specified regulatory and sales milestones are met; $100,000 was accrued at quarter-end. The first Phase III/pivotal-trial dosing milestone includes $200,000 plus $500,000 in company shares. The office lease runs through June 2016, with $242,000 in future minimum payments at quarter-end.
- The company changed its stock-option valuation method from a binomial model to Black-Scholes on July 1, 2015; it reported no material financial-statement impact. Management stated disclosure controls were effective and there were no material changes in internal control over financial reporting.
Important facts for investors to verify
- Confirm the intended issuer and reporting period: the supplied filing is for MEI Pharma, Inc., not Lite Strategy, Inc., and covers the quarter ended September 30, 2015.
- Review subsequent clinical data and development decisions, especially Pracinostat efficacy and survival findings and the planned PWT143 patient study.
- Assess cash runway against ongoing clinical-development costs and the timing and terms of any future financing or partnership.
- Confirm the status and likelihood of contingent S*Bio milestones and other contractual commitments.
- Consider dilution exposure: 34.156 million common shares were outstanding at September 30, 2015, alongside options, RSUs, and warrants.